{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:05:01Z","timestamp":1791518701204,"version":"4.3.4"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejca.2024.113531","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T08:18:12Z","timestamp":1704961092000},"page":"113531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial"],"prefix":"10.1016","volume":"199","author":[{"given":"Anna Maria","family":"Di Giacomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion-Sileni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Francesco","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Guidoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Covre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Camerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2024.113531_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1426-2","article-title":"Immunotherapy of brain metastases: breaking a \"dogma","volume":"38","author":"Di Giacomo","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2024.113531_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00001-8","article-title":"Nivolumab plus ipilimumab in melanoma brain metastases","volume":"23","author":"Di Giacomo","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.113531_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2022.11.012","article-title":"Immunotherapy for brain metastases and primary brain tumors","volume":"179","author":"Di Giacomo","year":"2023","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2024.113531_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(12)70324-8","article-title":"Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial","volume":"13","author":"Di Giacomo","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.113531_bib5","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/annonc\/mdu577","article-title":"Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study","volume":"26","author":"Di Giacomo","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.113531_bib6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2024.113531_bib7","first-page":"v533","article-title":"Long-term outcomes from the randomized ph 2 study of nivolumab (nivo) or nivo+ ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): anti-PD1 Brain Collaboration (ABC)","volume":"30","author":"Long","year":"2019","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2024.113531_bib8","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-21-1046","article-title":"Primary analysis and 4-year follow-up of the Phase III NIBIT-M2 trial in melanoma patients with brain metastases","volume":"27","author":"Di Giacomo","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.113531_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2017.05.031","article-title":"Health-related quality of life results from the phase III CheckMate 067 study","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113531_bib10","unstructured":"Fayers PM, 2021. The EORTC-QLQ-C30 Scoring Manual (3rd Edition). EORTC, Brussels, Belgium (2021)."},{"issue":"12","key":"10.1016\/j.ejca.2024.113531_bib11","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.113531_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/imt-2022-0262","article-title":"Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy","volume":"15","author":"Thompson","year":"2023","journal-title":"Immunotherapy"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2024.113981","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T05:06:38Z","timestamp":1729141598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":12,"alternative-id":["S0959804924000078"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113531","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2024.113981","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113531"}}